The Brazil In Vitro Diagnostics Market size is estimated at USD 2.12 billion in 2024, and is expected to reach USD 2.87 billion by 2029, growing at a CAGR of 6.12% during the forecast period (2024-2029).
The COVID-19 pandemic significantly impacted Brazil in-vitro diagnostics market. For instance, as per a May 2020 update, Brazil's National Health Surveillance Agency (ANVISA) expedited emergency reviews and approvals for medical devices and in-vitro diagnostics (IVDs) related to the COVID-19 pandemic. The agency allowed the emergency use of information from foreign regulatory authorities that participate in the Medical Device Single Audit Program (MDSAP) in place of its own good manufacturing practice inspections.
The major factors fueling the market growth are the high prevalence of chronic diseases and the increasing use of point-of-care diagnostics.
The high prevalence of chronic diseases is a major factor driving the market growth. According to World Population Ageing 2019, the number of people aged above 65 years in 2019 in Brazil region are 19.526 million and is expected to reach 52.026 million by 2050. This increase in geriatric population is expected to increase the prevalence rate of liver cancer in the country as elderly people are more prone to chronic diseases, thus boosting the market. Additionaly, leukemia is the most common cancer in children and has the incidence rates in industrialized countries, followed by developing countries. As per the GLOBOCAN 2020, 11,396 cases of leukemia were identified in Brazil in 2020 including both males and females of all ages. Such a prevalence indicates the rising demand for acute myeloid leukemia treatment in the country.
However, stringent regulations is a major factor hindering the Brazil in-vitro diagnostics market growth.
Factors, such as large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, and rapidly evolving technology, are driving the growth of the molecular diagnostics segment. For instance, in November 2020, Chembio Diagnostics, Inc. a leading point-of-care diagnostic company focused on infectious diseases, revealed that its subsidiary Chembio Diagnostics Brazil Ltda. received Agência Nacional de Vigilância Sanitária (ANVISA) approval for the DPP SARS-CoV-2 Antigen test system in Brazil.
The use of molecular diagnostic techniques in the development and subsequent administration of personalized medicine is likely to boost the market growth. For instance, in January 2022, the Oswaldo Cruz Foundation finished the development of two new molecular tests for the diagnosis of COVID-19, including one test submitted to ANVISA.
Thus, due to the above-mentioned factors, the market is expected to witness a significant growth over the forecast period.
This product will be delivered within 2 business days.
The COVID-19 pandemic significantly impacted Brazil in-vitro diagnostics market. For instance, as per a May 2020 update, Brazil's National Health Surveillance Agency (ANVISA) expedited emergency reviews and approvals for medical devices and in-vitro diagnostics (IVDs) related to the COVID-19 pandemic. The agency allowed the emergency use of information from foreign regulatory authorities that participate in the Medical Device Single Audit Program (MDSAP) in place of its own good manufacturing practice inspections.
The major factors fueling the market growth are the high prevalence of chronic diseases and the increasing use of point-of-care diagnostics.
The high prevalence of chronic diseases is a major factor driving the market growth. According to World Population Ageing 2019, the number of people aged above 65 years in 2019 in Brazil region are 19.526 million and is expected to reach 52.026 million by 2050. This increase in geriatric population is expected to increase the prevalence rate of liver cancer in the country as elderly people are more prone to chronic diseases, thus boosting the market. Additionaly, leukemia is the most common cancer in children and has the incidence rates in industrialized countries, followed by developing countries. As per the GLOBOCAN 2020, 11,396 cases of leukemia were identified in Brazil in 2020 including both males and females of all ages. Such a prevalence indicates the rising demand for acute myeloid leukemia treatment in the country.
However, stringent regulations is a major factor hindering the Brazil in-vitro diagnostics market growth.
Brazil In-Vitro Diagnostics Market Trends
Molecular Diagnostics Segment is Expected to Witness a Significant Growth
By test type, molecular diagnostics are expected to witness significant growth. Molecular diagnostic devices are used to analyze biological markers in the genome and proteome to detect pathogens or mutations.Factors, such as large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, and rapidly evolving technology, are driving the growth of the molecular diagnostics segment. For instance, in November 2020, Chembio Diagnostics, Inc. a leading point-of-care diagnostic company focused on infectious diseases, revealed that its subsidiary Chembio Diagnostics Brazil Ltda. received Agência Nacional de Vigilância Sanitária (ANVISA) approval for the DPP SARS-CoV-2 Antigen test system in Brazil.
The use of molecular diagnostic techniques in the development and subsequent administration of personalized medicine is likely to boost the market growth. For instance, in January 2022, the Oswaldo Cruz Foundation finished the development of two new molecular tests for the diagnosis of COVID-19, including one test submitted to ANVISA.
Thus, due to the above-mentioned factors, the market is expected to witness a significant growth over the forecast period.
Brazil In-Vitro Diagnostics Industry Overview
Danaher Corporation, Roche Diagnostics, Becton, Dickinson and Company, bioMérieux, and Bio-Rad Laboratories Inc. are some of the major players in the market studied. The major companies are focusing on increasing technological advancements, in order to address customer needs, like fully automated systems, which reduces manual processes and consumables and also provides fast and accurate results.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value -USD Million)
6 COMPETITIVE LANDSCAPE
Methodology
LOADING...
